Business
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenzaHantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its novel direct-acting antivirals demonstrate pan
About this update from Cocrystal Pharma, Inc.
[{"type":"image","alt":"Cocrystal Pharma, Inc.","displaySize":"","headline":null,"caption":"Cocrystal Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":232,"url":"https://media.zenfs.com/en/globenewswire.com/08f29bc54b812697c4622bc8896492a4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9OFbq_FaF00JEX7YQYA8ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMyNQ--/https://media.zenfs.com/en/globenewswire.com/08f29bc54b812697c4622bc8896492a4","width":300,"height":232},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/9OFbq_FaF00JEX7YQYA8ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMyNQ--/https://media.zenfs.com/en/globenewswire.com/08f29bc54b812697c4622bc8896492a4","width":300,"height":232}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenza","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Hantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":316,"olType":false},{"type":"text","content":"BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its novel direct-acting antivirals demonstrate pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These antiviral molecules target a highly conserved region of the viral replication enzyme, specifically the L-protein of Andes hantavirus, which is essential for viral replication and transcription. In vitro potency data show superior activity (IC50 <50 nM) against hantaan virus, which is closely related to the Andes hantavirus strain associated with recent outbreaks.","length":647,"tagName":"p"},{"type":"text","content":"“We are thoughtfully leveraging our expertise in viral replication enzymes and structure-based drug discovery to develop the next generation of pan-viral replication inhibitors. Our first pan-viral protease inhibitor, CDI-988, recently advanced to a Phase 1b norovirus challenge study in the United States. Our research efforts have expanded to novel pan-viral replication inhi...